Skip to main content

Table 1 Characteristics of patients treated versus not treated with SGLT2i or GLP-1 RA at last follow-up

From: Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

 

SGLT2i or GLP-1 RA

Standardized Difference (%)a

Yes

n = 2348

No

n = 12,228

Patient factors at enrollment

 Age (years)

56.1 ± 11.5

57.7 ± 12.1

13.8

 Female

42.4%

46.8%

8.8

Education level

  

26.2

 Primary or none

10.1%

20.0%

 

 Secondary

51.6%

49.1%

 

 University

37.3%

30.9%

 

 Current smoker

18.0%

12.5%

21.5

 Body mass index (kg/m2)

31.8 ± 6.5

28.9 ± 5.8

47.0

 Duration of diabetes

5.6 ± 5.0

5.8 ± 5.3

3.9

 HbA1c (%)

8.3 ± 1.6

8.3 ± 1.7

2.6

 Creatinine (mg/dL)

0.9 ± 1.0

1.0 ± 1.0

5.1

Specialty of Main Investigator

  

28.3

 Primary care

20.2%

31.4%

 

 Endocrinology

74.0%

65.5%

 

 Cardiology

4.7%

2.4%

 

 Other

1.1%

0.7%

 

Region

  

60.3

 Africa

0.6%

6.5%

 

 Americas

18.1%

12.8%

 

 Europe

34.1%

21.8%

 

 Middle East

11.7%

15.5%

 

 Southeast Asia

10.3%

25.4%

 

 Western Pacific

25.2%

17.9%

 

Comorbidities at last follow-up

 Coronary artery disease

14.8%

10.1%

14.4

 Cerebrovascular disease

2.9%

2.9%

0.2

 Heart failure

7.5%

4.3%

13.2

 Peripheral artery disease

3.4%

3.3%

0.6

 Chronic kidney disease

6.1%

5.1%

4.6

  1. a > 10% difference is considered clinically relevant